Nuvectis Pharma (NVCT) Competitors $8.83 -0.19 (-2.11%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$8.83 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NVCT vs. NTLA, CRON, REPL, IMTX, GYRE, DAWN, VIR, AVXL, ABUS, and EOLSShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Intellia Therapeutics (NTLA), Cronos Group (CRON), Replimune Group (REPL), Immatics (IMTX), Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Its Competitors Intellia Therapeutics Cronos Group Replimune Group Immatics Gyre Therapeutics Day One Biopharmaceuticals Vir Biotechnology Anavex Life Sciences Arbutus Biopharma Evolus Intellia Therapeutics (NASDAQ:NTLA) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings. Does the media prefer NTLA or NVCT? In the previous week, Intellia Therapeutics had 9 more articles in the media than Nuvectis Pharma. MarketBeat recorded 10 mentions for Intellia Therapeutics and 1 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 1.87 beat Intellia Therapeutics' score of 0.59 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Overall Sentiment Intellia Therapeutics Positive Nuvectis Pharma Very Positive Do insiders and institutionals hold more shares of NTLA or NVCT? 88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 30.5% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, NTLA or NVCT? Intellia Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Is NTLA or NVCT more profitable? Intellia Therapeutics' return on equity of -49.34% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% Nuvectis Pharma N/A -155.80%-104.02% Which has stronger earnings and valuation, NTLA or NVCT? Nuvectis Pharma has lower revenue, but higher earnings than Intellia Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$45.57M19.03-$481.19M-$5.23-1.60Nuvectis PharmaN/AN/A-$22.26M-$1.13-7.81 Do analysts prefer NTLA or NVCT? Intellia Therapeutics currently has a consensus price target of $34.95, suggesting a potential upside of 317.56%. Nuvectis Pharma has a consensus price target of $17.00, suggesting a potential upside of 92.53%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.67Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in NTLA or NVCT? Intellia Therapeutics received 436 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 92.86% of users gave Nuvectis Pharma an outperform vote while only 68.76% of users gave Intellia Therapeutics an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes44968.76% Underperform Votes20431.24% Nuvectis PharmaOutperform Votes1392.86% Underperform Votes17.14% SummaryIntellia Therapeutics beats Nuvectis Pharma on 10 of the 17 factors compared between the two stocks. Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.49M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-7.618.7827.1720.06Price / SalesN/A255.64410.88157.10Price / CashN/A65.8538.2534.64Price / Book12.616.557.094.70Net Income-$22.26M$143.93M$3.23B$247.88M7 Day Performance-1.56%3.97%2.91%2.66%1 Month Performance5.24%11.32%9.09%6.40%1 Year Performance32.78%4.20%31.75%14.07% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma2.8033 of 5 stars$8.83-2.1%$17.00+92.5%+33.2%$184.49MN/A-7.618Positive NewsNTLAIntellia Therapeutics4.5892 of 5 stars$7.16+4.2%$36.75+413.3%-64.8%$741.65M$45.57M-1.32600Analyst RevisionGap UpHigh Trading VolumeCRONCronos Group1.702 of 5 stars$1.92-3.0%N/A-21.0%$739.98M$124.59M-14.77450Positive NewsREPLReplimune Group4.5049 of 5 stars$9.57+6.6%$19.75+106.4%+8.7%$737.72MN/A-3.12210Positive NewsHigh Trading VolumeIMTXImmatics2.6358 of 5 stars$6.01+11.5%$14.67+144.0%-55.1%$730.52M$144.15M-9.11260Analyst RevisionGap UpHigh Trading VolumeGYREGyre Therapeutics0.367 of 5 stars$7.68-15.3%N/A-21.8%$720.06M$100.64M384.0040Short Interest ↓High Trading VolumeDAWNDay One Biopharmaceuticals1.7291 of 5 stars$7.01+9.9%$30.57+336.1%-46.2%$710.55M$161.92M-6.8160VIRVir Biotechnology3.0632 of 5 stars$5.07+2.6%$32.86+548.1%-50.6%$700.87M$14.30M-1.29580Positive NewsAVXLAnavex Life Sciences3.9111 of 5 stars$7.56+0.4%$44.00+482.0%+121.6%$645.41MN/A-13.7540Positive NewsABUSArbutus Biopharma2.2275 of 5 stars$3.36flat$5.50+63.7%+10.1%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus4.115 of 5 stars$9.97+8.5%$23.75+138.2%-11.6%$642.83M$275.46M-10.96170Positive NewsInsider TradeGap UpHigh Trading Volume Related Companies and Tools Related Companies NTLA Alternatives CRON Alternatives REPL Alternatives IMTX Alternatives GYRE Alternatives DAWN Alternatives VIR Alternatives AVXL Alternatives ABUS Alternatives EOLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NVCT Stock Free NVCT Stock Alerts